SIRT1 and B-cell non-Hodgkin lymphoma: In rare B-cell lymphomas, such as primary effusion lymphoma, SIRT1 has been shown to be necessary for the proliferation and maintenance of tumor cells, while SIRT1 inhibitors, such as Tenovim-6, efficiently decrease the neoplastic growth process [55].